1. Home
  2. MURA vs DYAI Comparison

MURA vs DYAI Comparison

Compare MURA & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MURA
  • DYAI
  • Stock Information
  • Founded
  • MURA 2013
  • DYAI 1979
  • Country
  • MURA Ireland
  • DYAI United States
  • Employees
  • MURA N/A
  • DYAI N/A
  • Industry
  • MURA
  • DYAI Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • MURA
  • DYAI Health Care
  • Exchange
  • MURA Nasdaq
  • DYAI Nasdaq
  • Market Cap
  • MURA 30.7M
  • DYAI 30.2M
  • IPO Year
  • MURA N/A
  • DYAI 2004
  • Fundamental
  • Price
  • MURA $1.82
  • DYAI $0.80
  • Analyst Decision
  • MURA Strong Buy
  • DYAI Strong Buy
  • Analyst Count
  • MURA 3
  • DYAI 1
  • Target Price
  • MURA $12.00
  • DYAI $6.00
  • AVG Volume (30 Days)
  • MURA 281.7K
  • DYAI 252.8K
  • Earning Date
  • MURA 08-04-2025
  • DYAI 08-13-2025
  • Dividend Yield
  • MURA N/A
  • DYAI N/A
  • EPS Growth
  • MURA N/A
  • DYAI N/A
  • EPS
  • MURA N/A
  • DYAI N/A
  • Revenue
  • MURA N/A
  • DYAI $4,135,078.00
  • Revenue This Year
  • MURA N/A
  • DYAI $22.56
  • Revenue Next Year
  • MURA N/A
  • DYAI $30.95
  • P/E Ratio
  • MURA N/A
  • DYAI N/A
  • Revenue Growth
  • MURA N/A
  • DYAI 129.20
  • 52 Week Low
  • MURA $0.95
  • DYAI $0.71
  • 52 Week High
  • MURA $4.74
  • DYAI $2.20
  • Technical
  • Relative Strength Index (RSI)
  • MURA 36.95
  • DYAI 35.25
  • Support Level
  • MURA $1.53
  • DYAI $0.71
  • Resistance Level
  • MURA $1.83
  • DYAI $0.90
  • Average True Range (ATR)
  • MURA 0.17
  • DYAI 0.08
  • MACD
  • MURA -0.01
  • DYAI -0.03
  • Stochastic Oscillator
  • MURA 33.33
  • DYAI 19.34

About MURA Mural Oncology plc

Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.

About DYAI Dyadic International Inc.

Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.

Share on Social Networks: